Discussion
Silexion Therapeutics has launched a Phase 2/3 clinical trial testing its experimental therapy SIL204 in combination with standard-of-care chemotherapy in people with pancreatic…
Pancreatic cancer is a rare form of cancer that begins in the pancreas, an essential organ involved in digestion and blood sugar control, but can spread, or metastasize, to other parts of the body. The disease can cause symptoms such as abdominal pain, nausea, fatigue, and jaundice, or a yellowing of the skin and eyes. However, diagnosing pancreatic cancer is difficult because most of its symptoms are unspecific and don’t become evident until the disease has already advanced significantly.
Treatment for pancreatic cancer, a rare cancer that arises from cells in the pancreas, may involve a variety of different approaches, depending on factors such as the stage of disease and a person’s health status. Due to the aggressive nature of the disease, pancreatic cancer survival rates are relatively low. An early diagnosis, when the cancer can still be treated with potentially curative surgery, is critical to improve a person’s pancreatic cancer prognosis. When surgery is not an option, chemotherapy, radiation, and other supportive care measures may help control the cancer and keep patients comfortable for as long as possible.
Discussion
PANCREATIC CANCER
Silexion Therapeutics has launched a Phase 2/3 clinical trial testing its experimental therapy SIL204 in combination with standard-of-care chemotherapy in people with pancreatic…
Discussion
PANCREATIC CANCER
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly’s experimental medication olomorasib as a potential treatment for previously…
Discussion
PANCREATIC CANCER
An anticancer vaccine targeting a common genetic driver of pancreatic cancer was shown to be safe in an early clinical trial, with the results…
Discussion
PANCREATIC CANCER
A $16 million research initiative is bringing together scientists from six U.S. cancer centers to build on recent breakthroughs in targeted therapies and develop longer-lasting…
Discussion
PANCREATIC CANCER
Dosing has begun in a global clinical trial testing Revolution Medicines‘ RAS(ON) inhibitor candidate zoldonrasib as a first-line treatment for advanced pancreatic ductal carcinoma…
Discussion
PANCREATIC CANCER
Treatment with Revolution Medicines‘ oral daraxonrasib more than doubled overall survival versus standard chemotherapy among adults with previously treated metastatic pancreatic cancer in…
Don't have an account?
|
Already have an account?
Create your account by filling in the information below:
By creating an account, you are agreeing to the Privacy Policy and Terms of Service.